Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

Microdosing glp-1 is gaining traction, but is it safe? Experts warn about compounded semaglutide, reduced efficacy, and ...

The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...

Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...